Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RBM12B divergent transcript (RBM12B-DT) refers to a transcript annotated near or overlapping the RNA binding motif protein 12B (**RBM12B**) gene, but does not correspond to a known protein-coding gene or established protein target. The "-DT" (divergent transcript) suffix is a nomenclature convention typically used in Ensembl and GENCODE transcript databases for non-coding or bidirectional transcripts that are found in genomic proximity to a coding gene, in this case, **RBM12B**. There is no evidence in publicly available biomedical databases or the peer-reviewed literature that RBM12B-DT encodes a protein, acts as a therapeutic target (such as a receptor, enzyme, transporter, or transcription factor), or is implicated in drug targeting or clinical biomarker research. The canonical gene **RBM12B** is an RNA-binding protein thought to be involved in RNA splicing[5], but RBM12B-DT itself is distinct from RBM12B and lacks detailed molecular or functional characterization. **Summary of findings:** - RBM12B-DT is not a well-defined molecular target. - It may be a non-coding RNA; there is no known protein product or functional data. - The entry is likely not suitable as a therapeutic target unless new data emerge. - If you are seeking information on the protein-coding gene *RBM12B* (RNA binding motif protein 12B), refer to that specifically; RBM12B is an RNA binding protein involved in RNA splicing, but RBM12B-DT is a distinct, poorly characterized transcript[5]. If your intent was to identify a targetable protein, RBM12B-DT does not fit this classification. You may want to clarify or directly reference the protein-coding RBM12B if that was the intended target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RBM12B divergent transcript (RBM12B-DT).